ALK and lung cancer: This is supported by data specifically in lung cancer showing that the incidence of NTRK fusions is approximately 0.1–0.3% overall, but is enriched approximately 10-fold in tumors with no other identified oncogenic driver (e.g., EGFR, ALK, ROS1, or RET alterations)16,17,21,22.